Diabetes, Vol 34, Issue 3 235-240, Copyright © 1985 by American Diabetes Association
Impaired insulin biosynthetic capacity in a rat model for non-insulin-dependent diabetes. Studies with dexamethasone
SJ Giddings, MJ Orland, GC Weir, S Bonner-Weir and MA Permutt
These studies of a rat model for non-insulin-dependent diabetes mellitus
(NIDDM) were performed to determine whether hyperglycemia occurs when
capacity to synthesize insulin is exceeded. The neonatal streptozocin
(STZ)-treated rat has acute hyperglycemia with marked destruction of
pancreatic beta-cells, followed by gradual regeneration to 50-70% normal
beta-cell number. At age 4 wk, fed serum glucose concentration is only
mildly elevated relative to controls. With age, the rats become
progressively hyperglycemic, and by 12 wk they have marked impairment of
glucose-stimulated insulin release. In these studies, dexamethasone (0.125
mg/kg/day for 4 days) was administered to control and to STZ-treated
animals to produce insulin resistance. The relationship between insulin
biosynthesis and serum glucose concentrations was assessed. In control
rats, response to dexamethasone was similar at both 4 and 12 wk. Serum
glucose levels and pancreatic insulin concentration remained unchanged.
Both insulin biosynthetic rates (as measured by 3H-leucine incorporation
into proinsulin) and proinsulin mRNA levels increased twofold. STZ-treated
rats at age 4 wk demonstrated mild hyperglycemia. Dexamethasone injection
resulted in an increase in insulin biosynthesis and proinsulin mRNA in
these animals, while serum glucose did not increase. STZ-treated rats at 12
wk showed more profound hyperglycemia (serum glucose 315 +/- 38 mg/dl
versus control, 187 +/- 12 mg/dl). A marked rise in serum glucose (to 519
+/- 42 mg/dl) was observed after 4 days of dexamethasone injection.
Pancreatic insulin content became severely depleted relative to
saline-injected, STZ-treated animals, and there was no response of levels
of proinsulin mRNA.